Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Mirati Therapeutics

Bristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.

Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal

Bristol-Myers Squibb Co (NYSE:BMY) has unveiled plans to buy Mirati Therapeutics (NASDAQ:MRTX) in a deal that values the cancer drug developer at up to $5.8 billion. This acquisition aims to diversify Bristol's cancer treatment offerings and mitigate anticipated revenue losses due to upcoming patent expirations.

Bristol-Myers Squibb enhances oncology portfolio in deal worth up to $5.8bn

The acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb's best-selling products.

Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion

Bristol-Myers Squibb enahnces oncology portfolio in deal worth up to $5.8bn

Bristol Myers Squibb Co. said Sunday it will buy Mirati Therapeutics Inc. in a deal valued at up to $5.8 billion.

Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion

The deal expands the pharmaceutical company's portfolio of cancer drugs.

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion

Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity value.

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc.® (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash, represent.

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Goals include expanded patient access to underserved populations, faster results, and reduced provider burden COLUMBUS, Ohio , Oct. 6, 2023 /PRNewswire/ -- Paradigm announced today a collaboration with Bristol Myers Squibb (NYSE: BMY) to build a new end-to-end clinical trial operating model across design, recruitment, and data collection. Starting with oncology and expanding to other therapeutic areas, Paradigm will enable Bristol Myers Squibb to enroll patients from providers across the Paradigm Network of health systems, all of whom serve diverse groups of patients and already use Paradigm software to reduce the burden of clinical trial recruitment and operations.

Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials

Duke Energy

Gilead Sciences

Verizon

Public Storage

The risk to the market is mounting, and with it, volatility. The VIX is up nearly 50% in the last month and heading higher, which means the S&P 500 could be heading lower.

5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio

Agilent Technologies

Analog Devices

Autodesk

Amazon

American Express

Boeing

Bank of America

Biogen

Bank of New York Mellon

Blackrock Inc

Colgate-Palmolive

Clorox

Comcast

Compass Minerals

Campbell Soup

Salesforce

Corteva Inc

Disney

Ecolab

Equifax

Estee Lauder

Etsy

Fortinet

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

U.S. Wide-Moat Stocks On Sale - The October 2023 Heat Map

Johnson & Johnson

Eli Lilly

Merck

Major drugmakers including Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and Merck & Co Inc (NYSE:MRK) have agreed to participate in the Inflation Reduction Act's (IRA's) Medicare Drug Price Negotiation Program, the Biden administration said on Tuesday. The Inflation Reduction Act of 2022 granted the ability for Medicare to negotiate drug prices directly with manufacturers with the aim of reducing the costs of medications for seniors and other Medicare beneficiaries.

Drugmakers agree to participate in Medicare price negotiations

Arcellx

Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients' T cells, which fight hostile cells within the body.

Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs

AbbVie

Amgen

Novartis

The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.

Drugmakers opt in to Medicare drug price negotiations – here's what happens next

Pfizer

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to participate in the talks by the Oct. 1 deadline.

Drugmakers sign on to negotiate Medicare prices under protest

AstraZeneca

Novo Nordisk

A federal judge dealt a blow to hopes for a near-term injunction to halt the federal government plan to let Medicare to pay less for a few expensive medicines.

Big Pharma Can't Stop the Price-Negotiation Program. What's Next.

With a few exceptions, pharmaceutical stocks have underperformed the broader market this year. The S&P Pharmaceutical Index is down 3% year to date versus a 12% gain in the benchmark S&P 500.

Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024

Bristol-Myers Squibb stock has hit a new low and is currently out of favor in the market. The company's revenue has been affected by the loss of a key drug, but it has a strong pipeline of new drugs with potential for significant sales growth. The company announced a $4 billion ASR and already offers a nearly 4% dividend yield.

Bristol-Myers: Out Of Favor (Rating Upgrade)

Apple

Bristol Myers, Apple, and Verizon have been increasing their dividends in recent years. All three companies have sustainable payouts that should also rise in the future.

3 Dividend Stocks to Buy and Hold Until Retirement

Returning to the pre-inflation shock level of over $80 means that BMY stock will have to gain more than 35% from here, and we think it will likely materialize over time.

Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80?

PRESS RELEASE Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb Cambridge, UK, September 26 th , 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone. This follows the announcement of the first milestone achieved in the first discovery programme on May 4, 2023.

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

PRINCETON, N.J.--(BUSINESS WIRE)---- $bmy #bristolmyerssquibb--Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023.

Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023

Following a potential false breakout, Bristol Myers Squibb declined about 27% from its previous all-time high, and the stock might decline further. The company is facing several risks - including political risks like Medicare trying to lower prices or Bristol Myers Squibb struggling to grow (aside from the Celgene acquisition). Even when assuming rather low growth rates, the stock still seems undervalued, and BMY seems like a solid investment.

Bristol Myers Squibb: Undervalued Already, But Could Go Lower

Since Bristol Myers Squibb acquired Celgene for $74 billion in 2019, the stock price has faced challenges and stagnation. The company's defensive strategy to defend the value of its legacy products may not be successful, given impending patent expirations and pricing pressures. BMY envisions a transformation in its revenue composition by 2030, driven by a new product portfolio, but significant changes are unlikely in the next three years.

Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years

BeiGene

Kezar Life Sciences Inc

Ocular Therapeutix

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.

News for Bristol-Myers Stock (BMY)